Episode Details

Modernas post-pandemic slump may be over as investors show renewed interest in the companys messenger RNA technology, driving the stock up by over seventy percent since January. The company has expanded beyond coronavirus products, winning approval for a respiratory syncytial virus vaccine and a next-generation coronavirus shot, and has filed for a flu vaccine. Modernas pipeline also includes late-stage cancer vaccines, but full-year revenue hit just one point nine billion dollars in twenty twenty-five, alongside a net loss of two point eight billion dollars. Despite the recent losses, the companys recent momentum suggests a potential turnaround.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/f2ac2d54fa42287c